Tracer library / [213Bi]Bi-DOTA-TOC
[213Bi]Bi-DOTA-TOC
Also written as DOTATOC; DOTA-TOC
- Radionuclide
- Bi-213 t½ 45.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 0
What it is
- Compound class
- Somatostatin analogue peptide (DOTA-conjugated octreotide) radiolabelled with alpha-emitter
- Target / mechanism
- Somatostatin receptor (sstr) PMID 15778581
- Clinical application
- Neuroendocrine liver metastases refractory to beta-emitter DOTATOC therapy PMID 25070685
- Theranostic pair
- [68Ga]Ga-DOTA-TOC
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.2014 · Eur J Nucl Med Mol Imaging · Clinical study
Need this precursor?We can point you to suppliers for [213Bi]Bi-DOTA-TOC, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Stage 26: this agent has NO own synthesis/characterisation data in the current corpus -- its only linked run(s) were unlinked (empty-quote recheck: appeared only as a control/comparator or in the wrong article). Stage set/updated at stage 39 from PMID 25070685: 'Here we report the first-in-human experience with (213)Bi-DOTATOC targeted alpha therapy (TAT) in patients pretreated with beta emitters.'.